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Abstract 
More people die annually from cardiovascular disease than from any other cause. Two 
risk factors for cardiovascular disease are hyperlipidemia and inflammation. Current drugs that 
are prescribed to regulate lipid levels often have adverse effects such as liver dysfunction. Blue-
green algae (BGA), also known as cyanobacteria, have been consumed for years for their health 
benefits because they are believed to increase energy and prevent disease. One genus of edible 
blue-green algae is Spirulina plantesis (SP, Spirulina). Various studies have shown that Spirulina 
may have anti-cancer and anti-inflammation and anti-bacterial properties. In a previous study, 
Spirulina platensis lowered triglyceride and cholesterol levels in hyperlipidemic rats. The rats 
were fed a Spirulina supplemented diet and their lipid levels were measured by their fecal output 
and intestinal absorption. However, the study did not involve isolation of the compounds 
responsible for this biological activity. The goal of this project is to isolate the specific 
compound(s) responsible for the anti-inflammatory and hypolipidemic effects of Spirulina 
platensis.
 3
Introduction 
Cardiovascular disease is the number one cause of death in men and women in the United 
States (Ford 2012). Cardiovascular disease is defined as changes in the physiology and structure 
of the heart or blood vessels that impairs function (AHA 2015). This research project focused on 
two risk factors for cardiovascular disease: hyperlipidemia and inflammation. Inflammation is an 
immune system response to harmful stimuli. Hyperlipidemia is an increase in triglycerides in the 
blood plasma (Gotto 1977). Hypercholersterolemia is a subset of hyperlipidemia defined as an 
increase in total cholesterol levels in the blood (Gotto 1977). 
Hypercholesteromlemia can be familial or can be triggered by lifestyle and diet (Haines 
2013). The two processes involved in cholesterol regulation are cholesterol synthesis and 
cholesterol absorption from the diet. Cholesterol synthesis begins in the mevalonate pathway 
(Figure 1). The rate-limiting enzyme in cholesterol biosynthesis is 3-hydroxy-3-methyl-glutaryl-
CoA Reductase (HMG-CoA Reductase or HMGR), the enzyme that converts HMG-CoA into 
mevalonate (Haines 2013). Mevalonate is converted to squalene and then to lanosterol. There are 
two pathways that convert lanesterol to cholesterol: the Kandutch-Russell pathway and the Bloch 
pathway. The Kandutch-Russell pathway converts lanosterol to lathosterol and 7-
dehydrocholesterol before converting it to cholesterol while desmosterol is the intermediate in 
the Bloch pathway (Wu 2014) (Figure 2). The intermediates of cholesterol synthesis are used as 
biomarkers to determine the rate of in vivo cholesterol synthesis.
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Dietary cholesterol absorption begins in the small intestine. Cholesterol particles form 
micelles and pass from the lumen of the intestine into the blood (Elshourbagy 2014). Cholesterol 
is insoluble in the plasma and is transported as lipoproteins. The types of lipoproteins in 
circulation are high-density lipoproteins (HDL), intermediate density lipoproteins (IDL) low-
density lipoproteins (LDL) and very low-density lipoproteins (VDL) (Elshourbagy 2014). The 
level of density of the lipoproteins represents the amount of protein they carry, with HDL 
composed of the highest level of protein (Elshourbagy 2014). HDL and LDL are the most 
commonly monitored lipoproteins. HDL and LDL are colloquially referred to as “good 
cholesterol” and “bad cholesterol” respectively. HDL facilitates reverse cholesterol transport, the 
process in which excess cholesterol from cells is returned to the liver to be degraded 
(Elshourbagy 2014). Dyslipidemia is a decrease in the amount of HDL. LDL transports 
cholesterol from the liver to peripheral tissues. A buildup of LDL in the plasma leads to 
inflammation and atherosclerosis (Elshourbagy 2014). 
LDL buildup in blood vessels puts stress on the vessel walls (Salisbury 2014). This stress 
damages the vessel walls inducing the inflammatory response. Macrophages and other immune 
cells recruited as part of the inflammatory response secrete of pro-inflammatory cytokines such 
as tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β,IL-1B) (Salisbury2014). 
These cytokines further progress the inflammatory state. Animal studies have shown that HDL 
decreases inflammation by removing LDL from vessel walls (Elshourbagy 2014). 
The lipid hypothesis states that high LDL levels correlate positively with cardiovascular 
disease risk and high HDL levels correlate negatively (Tobert 2003). In 1984, the National 
Institute of Health began to urge physicians to monitor the diets and nutrition of their patients 
with hypercholesterolemia in order to control their LDL levels. The first drugs employed to treat 
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hypercholesterolemia inhibited enzymes at the end stages of the mevalonate pathway. However, 
most of these drugs had adverse side effects such as the development of cataracts and toxicity. 
As a result, research shifted to the rate-limiting enzyme in cholesterol synthesis, HMGR. The 
first HMGR inhibitor was called compactin. It was isolated from a bacterial broth culture by a 
Japanese scientist in the 1970’s.  The most common class of HMGR inhibitors is the statin 
family. Statins bind competitively to the enzyme’s active site. The first clinically approved statin, 
lovastatin, was isolated from a fermented Aspergillus terreus broth (Tobert 2003). Eight 
derivatives of lovastatin and compactin have been synthesized (Figure 5). Other treatments for 
hypercholesterolemia include fibrates, bile acid sequestrates, and nicotinic acid. 
Current treatment of hyperlipidemia focuses on monitoring specific lipid levels and 
reducing all cardiovascular disease risk factors. Data derived from clinical trials and 
observational studies have led to the development of three health questions recommended by the 
American Heart Association to determine therapy options. Rather than basing therapies solely on 
LDL levels, treatment intensity is decided based on age, comorbidity, in addition to LDL levels 
(Pines 2014). The most common drug therappies for hypercholesterolemia are statins in 
combination with diet modification.  Side effects of statin use include muscle and liver damage, 
impairment of cognitive function, and increased blood sugar (Dimmit 2015). 
Lipid metabolism and inflammation are interconnected. Circulating cholesterol and lipids 
are known to stimulate the inflammatory response (van Diepen 2013).  Pro-inflammatory 
cytokines also have a direct effect on lipid metabolism. As a result of this connection, lipid-
lowering drugs can also have anti-inflammatory effects. Statins, niacin, and fibrates decrease 
inflammation by interacting directly with inflammatory pathways (van Diepen 2013). Non-
steroidal anti-inflammatory drugs (NSAIDs) are a major class of drugs used to treat pain and 
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inflammation. Aspirin is an NSAID that decreases inflammation by reducing the synthesis of 
prostaglandins. High-dose aspirin treatment also reduce lipid and cholesterol levels (van Diepen 
2013). However, a study found that patients with cardiovascular disease who use the NSAIDs 
diclofenac and rofecoxib are five times as likely to suffer a myocardial infarction than patients 
with cardiovascular disease that don’t use those NSAIDs. (Schjerning 2014). 
One mechanism of action to reduce inflammation is to target pro-inflammatory cytokines. 
In low doses, a drug called methotrexate, serves as an anti-inflammatory drug by block the pro-
inflammatory cytokine interlukin-1beta from binding to its receptor (van Diepen 2013). 
Methotrexate has been shown to increase HDL levels in patients with rheumatoid arthritis (van 
Diepen 2013). Possible side effects from methotrexate use include gastrointestinal bleeding and 
edema. Tocilizumab, infliximab, and canakunimab also target pro-inflammatory cytokines. 
These drugs decrease the levels of the pro-inflammatory cytokines tumor necrosis factor alpha, 
interleukin 6 and interleukin-1beta respectively (van Diepen 2013).  Specifically, these drugs 
disrupt cytokine signaling by degrading the cytokine receptors. Anti-cytokine drugs can have 
adverse gastrointestinal effects and interact with medicines such as birth control and blood 
thinners. 
As a result of the side effect of common drug therapies, research on natural products with 
hypolipidemic properties is necessary. Historically, natural products have been the source of 
many drugs and drug therapies. Between the years 1981 and 2010, 34% of drugs based on small 
molecules came from natural product sources (Harvey 2015). Researchers have been analyzing 
techniques that have utilized natural products for years, such as traditional Chinese medicine, in 
an effort to find natural products that match their targets.
 Figure 5. Structures of lovastatin and compactin drug derivatives
8
 (Tobert 2003). 
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Natural product extracts usually contain multiple compounds, which can be obstacle or an 
advantage.  An array of compounds could mean that a single natural product could work on 
multiple targets. On the other hand, inactive compounds present in larger amounts may block the 
activity of less abundant active compounds. Complications with isolation and synthesizing of 
natural products have caused a decline in natural product drug discovery over the past two 
decades (Harvey 2015). 
Table 1 shows 23 natural compounds and extracts that decreased or inhibited HMGR and 
had additional hypolipidemic effects. The compounds and extracts are divided into in vivo and in 
vitro studies. Compounds are further divided by the method of action: transcriptional or 
enzymatic regulation.  
One of the particularly interesting compounds is naringenin, a flavonoid from grapefruit, 
exerts hypolipidemic effects in vitro. Rat hepatocytes treated with 200µM of naringenin had a 
60% reduction in triglyceride production. Naringenin also increased LDLR expression and 
decreased HMGR and HMG-CoA synthase (HMGCS) expression (Goldwasser 2010). HMGCS 
is an enzyme involved in cholesterol biosynthesis. This compound has great medicinal potential 
because it has shown anti-inflammatory and hypolipidemic effects in vivo and in vitro. 
Additionally, the effect of naringenin on fatty acid oxidation and cholesterol biosynthesis 
indicates that it may play an important role in the regulation of lipid metabolism (Goldwasser 
2010). 
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Table 1. Natural Products with hypolipidemic properties. 
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Figure 6. Structure of naringenin
 
 
Figure 7. Stuctures of active bergamot flavonoids (Mollace 2011
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 (Goldwasser 2010). 
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Another citrus plant with bioactivity is bergamot (Figure 7). Bergamot is known for its 
high content and diversity of flavonoids. In a clinical study, polyphenol fractions of bergamot 
juice were freeze-dried and turned into 500mg tablets. These tablets were given to an 
experimental group of patients with hypercholesterolemia once a day. The control group of 
hypercholesterolemic patients was given a daily 500mg placebo pill. After 30 days, patients who 
took the bergamot pills had a 20% reduction in total cholesterol and LDL cholesterol (Mollace 
2011). HPLC analysis of the bergamot fraction revealed five flavonoids that made up 26-28% of 
the active fraction (Mollace 2011) 
Spirulina platensis (also referred to as SP and Spirulina) is a prokaryotic blue green alga 
also known as cyanobacteria. These organisms are photosynthetic but do not have plant cell  
walls, nuclear membranes, or internal organelles, resembling bacterial cells (Singh 2007). 
Spirulina was first isolated from a freshwater river in 1827 (Ciferri 1983). Indigenous 
populations in Africa and Mexico are known to have cultivated Spirulina from lakes and 
consumed the dried alga (Ciferri 1983). Spirulina has many bioactive components such as 
chlorophylls, carotenoids, amino acids, minerals, phycocyanin and secondary metabolites (Singh 
2007) (Figure 8a). Spirulina is known as a superfood because of the abundance of nutrients it 
contains. The amounts of these various components depend on the environment in which the 
Spirulina is grown (Singh 2007). Cyanobacteria are known to have a diverse range of biological 
activity such as anti-malarial, anti-inflammatory, and anti-viral activity (Figure 8b).
  
Figure 8. A) Composition of Spirulina platensis. 
(Singh 2007). 
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B) known biological activity of cyanobacteria 
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In a previous studies done by Dr. Ji-Young Lee, the anti-inflammatory and hypolipidemic 
properties of two edible genera of blue-green algae have been shown (Yang 2011). An extract of 
the blue green algae Nostoc commune var. sphaeroides Kützing decreased the mRNA levels of 
pro-inflammatory cytokines, HMGR and the LDL receptor (LDLR) in RAW macrophages and 
HepG2 cells. In vivo studies of edible blue green algae with the C57BL/6J mice model of 
hyperlipidemia have had similar results. Mice fed a high fat diet supplemented with Nostoc and 
Spirulina for 4 weeks showed a change in the composition of intestinal bacteria and a decrease in 
plasma triglyceride and cholesterol levels (Rasmussen 2009). These hypolipidemic effects are 
attributed to an increased intestinal absorption of lipids and an increased fecal output (Ku 2013). 
The long-term effects of Spirulina and Nostoc were studied in vivo by supplementing the diets of 
mice with the BGA for six months. The mice from the experimental group showed no adverse 
affects in comparison to the control group. 
Although these studies have demonstrated the anti-inflammatory and hypolipidemic 
properties of blue-green algae, the compounds responsible the bioactivity are unknown. The goal 
of my project was to isolate the compound(s) responsible for the effects of Spirulina platensis. 
Compound structures will be determined and these will be tested on biological assays. 
 
Experimental 
Fifty grams of dried Spirulina was obtained from Earthrise Nutritionals in Irvine, CA. 
The dried algae was weighed and incubated overnight in 300mL of a 2:1 ratio of 
dichloromethane (DCM) to methanol.  After incubation, the alga and solvent were poured into a 
funnel with coarse filter paper to separate the solvent from the alga. The alga was incubated 8-10 
times until an exhaustive extraction was performed, resulting in 6.43 g of crude extract. The 
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crude extract was rehydrated with hexanes, combined with silica (Pittsburg, PA) and passed 
through a flash column. Solvents (500mL each) were passed through the column with added air 
pressure according to the following ratio:  A: 100% hexanes, B: 10% ethyl acetate 
(EtOAc)/hexanes, C: 20% EtOAc/hexanes, D: 40% EtOAc/hexanes, E: 60% EtOAc/hexanes, F: 
80% EtOAc/hexanes, G: 100% EtOAc, H: 25% MeOH/EtOAc, I: 100% MeOH, J: 100% DCM 
and 100% MeOH.  
 GAPSP1 fractions A-J were analyzed using liquid chromatography mass spectroscopy 
(LCMS) with Agilent ESI single quadrupole mass spectrometer (Santa Clara, CA) paired to 
Agilent high performance liquid chromatography (HPLC) system with a G1311 quaternary 
pump, G1322 degasser, and a G1315 diode array detector using an Eclipse XDB-C18 (4.6 × 150 
mm, 5 µm) RP-HPLC column. Fractions that had shown activity in the previous study were also 
tested on the Agilent HPLC system.  
The bioactivity of SP was tested for HMG-CoA Reductase (HMGR) expression by 
treating a HepG2 cell with the GAPSP1 fractions dissolved in dimethyl sulfoxide (DMSO) at a 
concentration of 50 µg/mL of media. The HepG2 cells were incubated for 24 hours. Interleukin-
1β (IL-1b) expression was tested using RAW 264.7 mice macrophage bioassay. The fractions 
were applied to at a concentration of 1 µg/mL. Before fractions were added, the macrophages 
were treated with 100 ng/mL of lipopolysaccharide (LPS) to stimulate inflammation.  
After analysis of the LCMS chromatograms, GAPSP1C was selected for further 
fractionation by reverse phase solid phase extraction (SPE) on a DSC-18 500mg column using 
60 mL of the following solvent systems: 1: 25% MeOH/ wawter (H2O) 2: 50% MeOH/H2O  3: 
75% MeOH/H2O 4: 100% MeOH 5: 100% EtOAc. 
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GAPSP1C fractions 1-5 were analyzed using LCMS. GAPSP1C4 was analyzed on HPLC 
using 75% ACN and 70% ACN. GAPSP1C4A, GAPSP1C4B, GAPSP1C4W, GAPSP1C4A.E 
were collected from GAPSP1C4 using HPLC at 60% ACN over 30 minutes (Figure 5).   
GAPSP1C4B was 60% pure and 0.84 mg of the compound was isolated (Figure 6). GAPSP1C 
and GAPSP1C4B proton NMR spectra were recorded on a Brüker Avance 500 MHz 
spectrometer (500.13 MHz 1 H, 125.65 MHz 13C). 
 
Results 
In our previous study, the D fraction (40% EtOAc/hexanes) eluted during the normal 
phase flash column chromatography of the initial crude SP extract, reduced IL-1B and HMGR 
expression (Figure 9).  Further HPLC isolation of the D fraction yielded compounds, 
CSKSP1D1+2. CSKSP1D1+2 was isolated at 40% ACN and eluted at 8.5-9.5 minutes. The 
isolated compounds also had a repressive effect on HMGR and IL-1B (Figure 10).  
A similar peak to those found in the original compound was found in the C fraction. 
GAPSP1C (Figure 15) eluted at 20% EtOAc/hexanes during normal phase flash column 
chromatography of the crude SP extract. SPE of GAPSP1C yielded five fractions. Compound 1 
and 2 were most prevalent in GAPSP1C4 but were also present in fractions GAPSP1C3, and 
GAPSP1C5. HPLC isolation at 60% ACN for 30 minutes yielded GAPSP1C4A eluted at 17 
minutes, GAPSP1C4B eluted at 26 minutes, GAPSP1C4A.E, and GAPSP1C4W (Figure 16). 
GAPSP1C4B is 60% pure and contains a similar peak to that found in CSKSP1D1+2 (Figure 
17). GAPSP1 fractions A, B, H, I, J repressed IL-1b expression in RAW 264.7 macrophages 
(Figure 14). The fractions did not show significant activity against HMGR expression. 
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Figure 9. Bioactivity of CSKSP fractions in A) HepG2 cells and B) RAW 264.7 macrophages 
(Ku 2014).
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Figure 10. Bioactivity of CSKSPD fraction and CSKSPD1+2 in A) HepG2 cells and B) RAW 
264.7  macrophages (Ku 2014).
	
Control SP-D 1+2 All Else
0.0
0.5
1.0
1.5
***
***
***
IL-1β
R
e
la
tiv
e
 
Ex
pr
e
s
s
io
n
	
HMGR LDLR
0.0
0.5
1.0
1.5
2.0
2.5
Control
SP-D
1+2
All Else
a
c c
b
a
b
c c
Re
la
tiv
e
 
Ex
pr
e
s
s
io
n
 19
 
Figure 11. A) HPLC chromatogram and B) mass trace of CSKSPD1+2.
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 Figure 12. Proton NMR spectrum of CSKSPD1+2
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 Figure 13. GAPSP1 fraction tree.  
 
Figure 14. IL-1b expression in RAW 264.7 macrophages after treatment with GAPSP1 
fractions. 
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Figure 15. A) HPLC chromatogram and B) mass trace of GAPSP1C. 
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Figure 16. HPLC chromatogram of GAPSP1C4 at 60%ACN over 30 minutes. GAPSP1C4A, 
GAPSP1C4B, GAPSP1C4A.E, GAPSP1C4W are highlighted.
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Figure 17. A) HPLC chromatogram and B) mass trace of GAPSP1C4B. 
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Figure 18. Proton NMR of GAPSP1C4
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Discussion 
Re-isolation of CSKSPD1+2 proved to be challenging because there was only a very 
small amount of the compounds isolated. This limited the number of analyses that could be 
performed. Also, large scale isolation of this compound was difficult because the active 
compound was a very small portion of the crude Spirulina extract. Further analysis will be done 
to determine if both compound 1 and 2 are active and if they act synergistically. 
The original mass that was sought after in the GAPSP1 fractions was 369.1. This was the 
mass of the most prevalent peak in the initial SP D fraction. Conversely, the isolated bioactive 
compound, CSKSPD1+2, does not contain a peak with that mass. Future studies will pursue the 
masses present in CSKSPD1+2.  
GAPSP1C fraction was not active in the HMGR or IL-1B bioassays. This may be a result 
of more abundant nuisance compounds overshadowing the anti-inflammatory or HMGR-
repressing compounds that are present in smaller amounts. GAPSP1C4B will be tested in the 
HMGR and IL-1B bioassays to analyze the bioactivity. However, because only 0.48 mg were 
isolated, more of the compound will be necessary for structure determination. 
CSKSPD1+2 activity against HMGR and IL-1B mRNA demonstrates that the 
compounds are active transcriptionally. Future studies should analyze if the compounds also 
inhibit the enzymatic activity of HMGR and/or prevent IL-1B from binding to its receptor. 
 
Conclusion and Future Directions 
The goal of this study was to isolate the compounds responsible for the hypolipidemic 
and anti-inflammatory effects of the edible blue-green alga, Spirulina platensis. Initial 
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fractionation of a crude Spirulina extract resulted in a bioactive D fraction which was further 
fractionated into the bioactive compounds CSKSPD1+2. A second fractionation of a crude 
Spirulina extract yielded a fraction, GAPSP1C that contained similar peaks to the original active 
D fraction. The peak of interest was isolated in GAPSP1C4B, but not enough of the compound 
was isolated to determine the chemical structure. Future studies will involve re-isolation of the 
compound and comparison of the bioactivity of GAPSP1C4B to CSKSPD1+2. Additionally, the 
synergistic activity of these two compounds and the other bioactive fractions will be analyzed.
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